Armata Pharmaceuticals, Inc. ARMP

NYSE; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0000921114

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $76.9M
Warnings	thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 25, 2026 231 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$3.77 2026-11-10; market equity $140.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 25, 2026

We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We have completed three Phase 2 clinical trials to date. We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 2.1						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(181.3%)	(6.6%)	2.1	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 81.4					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(25.10)	(0.35)	77.4	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	1.19x	2.95x	85.5	826	2025-12-31
Growth and financing, sleeve percentile 45.7					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	(7.1%)	2.2%	65.2	694	2025-12-31
Net share issuance, one year	1.2%	2.5%	26.2	628	2026-03-18

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-10 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(25.3%)	(1.9%)	33
Distance from 52-week high	(74.7%)	(28.5%)	10
EBIT to enterprise value	not computable	(1.6%)	
Free cash flow yield	(18.9%)	(1.0%)	24
Book value to price	(1.66)	0.27	1
Sales to price	not computable	0.29	
Composite equity issuance, five years	39.9%	20.8%	62
Relative strength against the sector, log excess return	(0.46)	(0.19)	33

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$24.0M
Operating cash flow, four quarters	-$25.4M
Months of runway	11.3
Days since last periodic filing	91 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$350,304

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$173.8M	2025-12-31	2026-03-25	10-K	26-034532
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$25.8M	2025-12-31	2026-03-25	10-K	26-034532
3	assets	us-gaap:Assets	$76.9M	2025-12-31	2026-03-25	10-K	26-034532
4	assets	us-gaap:Assets	$86.4M	2024-12-31	2026-03-25	10-K	26-034532
5	current assets	us-gaap:AssetsCurrent	$10.7M	2025-12-31	2026-03-25	10-K	26-034532
6	current liabilities	us-gaap:LiabilitiesCurrent	$8.9M	2025-12-31	2026-03-25	10-K	26-034532
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$501.5M	2025-12-31	2026-03-25	10-K	26-034532
8	operating income	us-gaap:OperatingIncomeLoss	-$36.6M	2025-12-31	2026-03-25	10-K	26-034532
9	book equity	us-gaap:StockholdersEquity	-$218.6M	2025-12-31	2026-03-25	10-K	26-034532
10	liabilities	us-gaap:Liabilities	$295.5M	2025-12-31	2026-03-25	10-K	26-034532
11	operating income	us-gaap:OperatingIncomeLoss	-$36.9M	2022-12-31	2024-03-21	10-K	24-003706
12	interest expense	us-gaap:InterestExpense	$0	2022-12-31	2023-03-16	10-K	23-004014
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$542,000	2025-12-31	2026-03-25	10-K	26-034532
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$37.6M	2024-12-31	2026-03-25	10-K	26-034532
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.9M	2024-12-31	2026-03-25	10-K	26-034532
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$47.4M	2023-12-31	2025-03-21	10-K	25-003406
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$8.1M	2023-12-31	2025-03-21	10-K	25-003406
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$32.5M	2022-12-31	2024-03-21	10-K	24-003706
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.2M	2022-12-31	2024-03-21	10-K	24-003706
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$875,000	2018-12-31	2020-03-19	10-K	20-002943
21	depreciation amortization	us-gaap:Depreciation	$1.4M	2018-12-31	2020-03-19	10-K	20-002943
22	operating income	us-gaap:OperatingIncomeLoss	-$17.7M	2018-12-31	2020-03-19	10-K	20-002943
23	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$16.7M	2018-12-31	2020-03-19	10-K	20-002943
24	income tax	us-gaap:IncomeTaxExpenseBenefit	-$328,000	2018-12-31	2019-03-25	10-K	19-015711
25	current assets	us-gaap:AssetsCurrent	$10.4M	2018-12-31	2020-03-19	10-K	20-002943
26	current liabilities	us-gaap:LiabilitiesCurrent	$2.0M	2018-12-31	2020-03-19	10-K	20-002943
27	current assets	us-gaap:AssetsCurrent	$5.4M	2017-12-31	2019-03-25	10-K	19-015711
28	current liabilities	us-gaap:LiabilitiesCurrent	$2.0M	2017-12-31	2019-03-25	10-K	19-015711
29	assets	us-gaap:Assets	$98.4M	2023-12-31	2025-03-21	10-K	25-003406
30	assets	us-gaap:Assets	$95.8M	2022-12-31	2024-03-21	10-K	24-003706
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	36,632,775	2026-03-18	2026-03-25	10-K	26-034532
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	36,183,067	2025-02-28	2025-03-21	10-K	25-003406

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.